Generics of Baraclude and Amosartan meet requirements for the Exclusive Sale Rights

As the Patent Linkage System passed the National Assembly, it is expected that some generics will acquire the Prioritized Sale Item Approval (Exclusive Sale Right) this year.

If the system will get enforced on the coming 15^th, pharmaceutical companies which succeed a patent challenge and apply for the approval will acquire the 9-month exclusive rights. In other words, the company will own the ...